ArticleJournal of comparative effectiveness research2025
Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US.
Article in Journal of comparative effectiveness research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach.Obesity (Silver Spring, Md.) · 2026Guideline
- GLP-1 receptor agonists for treating obesity without diabetes: A systematic review and meta-analysis of economic evaluations.Diabetes, obesity & metabolism · 2026Pooled it
- Integrating incretin-based therapies into comprehensive obesity care: an EASO position statement.The Lancet regional health. Europe · 2026Review
- Trends in Diagnosing Obesity: The CALOR Study.Obesity (Silver Spring, Md.) · 2026Article
- Epidemiology of osteoarthritis overall and by body mass index category in the United States: A retrospective analysis of the National Health and Nutrition Examination Survey.Obesity pillars · 2026Article
- Projected budget impact of pharmacotherapy scenarios for obesity and related conditions in Peru: A national survey analysis of 76,819 participants.Obesity pillars · 2026Article
- Real-World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan.Diabetes, obesity & metabolism · 2026Article
- Sulforaphane and Broccoli-Derived Preparations in Obesity and Obesity-Related Metabolic Dysfunction: Mechanistic Insights, Preclinical Evidence, and Clinical Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Review
- Novel Therapeutic Strategies for Patients With CKD and Diabetes Mellitus.Kidney international reports · 2026Review
- Racial and ethnic disparities in GLP-1 prescriptions among veterans with obesity across direct and community care settings.Health affairs scholar · 2026Article
- Patient Experiences With GLP-1 Receptor Agonists.JAMA network open · 2026Article
- ICER report demonstrates both the value and challenges in financing of weight loss medications.Journal of managed care & specialty pharmacy · 2026Article
- Joint TOS/OMA/OAC expert guidance statement on the pharmacological management of United States adults with overweight or obesity using the GRADE approach.Obesity pillars · 2026Article
- Future Directions in the Medical Treatment of Obesity: A Narrative Review.Advances in therapy · 2026Review
- Negative Consequences of Removing GLP-1 RA Obesity Coverage: A Cross-Sectional Cohort Comparison Study.Obesity science & practice · 2026Article
- Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders.Clinical and molecular hepatology · 2026Review
- Administrative costs of prior authorizations for glucagon-like peptide-1 agonists.Journal of managed care & specialty pharmacy · 2026Observational
- Trends in 1-year persistence and adherence among initiators of high-potency, weight loss-indicated glucagon-like peptide 1 receptor agonists.Journal of managed care & specialty pharmacy · 2026Article
- Considering Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) for Weight Loss: Insights from a Pragmatic Mixed-Methods Study of Patient Beliefs and Barriers.Healthcare (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucagon-like peptide 1 receptor agonists and glucagon-like peptide 1/gastric inhibitory polypeptide receptor agonists offer weight reduction and associated health benefits that, if sustained over time, have the potential to markedly improve population health. However, over 40% of US adults have obesity, translating into more than 100 million potential new users of obesity medications. Standing in the way of the major opportunity to improve health for these individuals is the massive and likely ongoing cost of treating such a large segment of the population, even though use of the treatments is estimated to be cost-effective over a lifetime. This paper analyzes the range of emerging market approaches and policy reforms that have the potential to help the broader US health system achieve affordable and equitable access to these medications, and the relative advantages, barriers and possible unintended consequences of each approach. We seek to present policymakers and industry leaders with insights and lessons learned from experts while offering a menu of options for the future that will help all stakeholders play an active part in an innovative future of pricing, coverage and payment for new obesity medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.